SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study

SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China, announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its SNK-2726. The angiotensinogen (AGT)-targeted small nucleic acid (siRNA) drug is expected to be assessed in subjects with mildly elevated blood pressure.

Drug Profile
SNK-2726 is administered subcutaneously and works by inhibiting the production of angiotensinogen (AGT) at its source. By blocking the renin-angiotensin-aldosterone system (RAAS), the drug aims to reduce systemic blood pressure. Preclinical results have demonstrated that SNK-2726 can significantly inhibit the synthesis of AGT in the liver, leading to a sustained decrease in AGT protein levels and exerting a long-lasting hypotensive effect with good safety.-Fineline Info & Tech